Australia Diabetes Care Drugs And Devices Market: Market Size & Forecast 2026

The Australia Diabetes Care Drugs and Devices market encompasses the full range of pharmacological treatments and medical devices used by people living with diabetes in Australia. It is currently valued at around USD 1.56 billion in 2025 and is forecast to grow at approximately 2.94% per year through 2031. Demand is shaped by the country's universal healthcare system, the Pharmaceutical Benefits Scheme (PBS), and the National Diabetes Services Scheme (NDSS), which together support broad patient access to therapies and supplies.

• •Market valued at approximately USD 1.56 billion in 2025.
• •Forecast CAGR of 2.94% through 2031.
• •Coverage spans oral antidiabetics, insulin therapies, glucose monitors, and delivery devices.

The principal driver is the steady rise in diabetes prevalence linked to ageing demographics, urbanisation, obesity, and sedentary lifestyles across Australia. Technological innovation in continuous glucose monitors (CGMs), smart insulin pens, and automated insulin delivery systems is accelerating device uptake among both type 1 and insulin-requiring type 2 patients. In parallel, the introduction of GLP-1 receptor agonists and dual GIP/GLP-1 agonists is reshaping the pharmacological landscape and expanding treatment options.

• •Rising diabetes prevalence tied to obesity and ageing populations.
• •Faster adoption of CGM and insulin pump technologies.
• •Expanded use of GLP-1 and dual incretin-based therapies.

The market is commonly segmented into drugs (oral antidiabetics, insulin, and non-insulin injectables) and devices (glucose monitoring systems and insulin delivery devices). Within devices, continuous glucose monitors represent the fastest-growing sub-segment, while insulin delivery is split between pumps, pens, and syringes. Geographically, New South Wales and Victoria account for the largest shares of patient volumes and spending, reflecting their higher population density and concentration of specialist diabetes centres.

• •Devices split into glucose monitoring and insulin delivery categories.
• •CGM is the fastest-growing device sub-segment.
• •New South Wales and Victoria lead in patient volumes and expenditure.

What are the recent trends and outlook?

Key trends include the shift from finger-stick testing to real-time CGM, growing reimbursement coverage for next-generation devices through the NDSS, and increasing prescription of GLP-1-based therapies for both glycaemic control and weight management. Integration of diabetes data with smartphone apps and cloud-based platforms is improving adherence and clinical decision-making. Looking ahead, the market is expected to maintain steady mid-single-digit growth, supported by demographic trends, technology adoption, and broader access to innovative therapies.

• •Reimbursement expansion for CGM and automated insulin delivery systems.
• •Rising use of connected health and digital diabetes management tools.
• •Steady growth expected as ageing and obesity trends sustain demand.